# BPC-157 TB-500 GHK-Cu Blend Dosage — Research Literature

> BPC-157 dosage ranges studied in preclinical literature: 10 μg/kg to 500 μg/kg across multiple routes. TB-500 and GHK-Cu research concentrations also covered. No human clinical dose established.

**Note:** All dosage figures below are from rodent preclinical studies. No clinical trial has established a therapeutic human dose for BPC-157, TB-500, or GHK-Cu, individually or in combination.

## BPC-157 Research Dosing Ranges

| Dose | Route | Model | Outcome | Ref |
|------|-------|-------|---------|-----|
| 10 μg/kg/day | IP | Rat Achilles tendon transection | Improved AFI, biomechanical properties | [4] |
| 10 μg/kg and 10 ng/kg | IP, oral, topical | Rat MCL | Consistent improvements over 90 days | [8] |
| 10 μg/kg and 10 ng/kg | IP and oral | Rat NSAID liver model | Normalized liver enzymes | [5] |
| 20–500 μg/kg | IM and IV | PK study — rat and dog | t½ ~15.2 min (rat IV); bioavailability 14–51% | [7] |
| 10 μg/kg | Oral (drinking water) | Rat IBD/mucosal models | Anti-ulcer, mucosal healing | [22] |

The BPC-157 dosage literature does not establish a human clinical dose. The three published human pilot studies did not report a standardized dose schedule [21].

TB-500 dose ranges in wound healing models span 0.5–10 mg/kg [22].

## BPC-157 TB-500 Blend Dosage Protocols in the Literature

Research vials most commonly reported at 5 mg:5 mg or 10 mg:10 mg — conventions built on individual compound data, not controlled combination trials [22]. The orders-of-magnitude difference in individual rodent dose ranges means the 5:5 convention is a practical compromise, not an evidence-based fixed ratio.

## BPC-157 Pharmacokinetics and Bioavailability

IV elimination half-life: ~15.2 min (rat), ~5.27 min (dog). IM bioavailability: 14–19% (rat), 45–51% (dog) [7]. Excretion primarily via urine and bile. Stable in gastric juice >24 hours — the mechanism for oral-route activity in rodent studies [7].

## Administration Routes Studied in BPC-157 Research

Intraperitoneal, subcutaneous, intramuscular, intravenous, oral gavage, oral drinking water, and topical cream. Consistent healing effects documented via all three primary routes (IP, topical, oral) in the MCL study over 90 days [8]. TB-500: topical, IP, subcutaneous [10][11]. GHK-Cu: topical, intradermal, systemic in animal models, liposomal topical [14][17].

## Injection Frequency in Research Protocols

BPC-157: once daily in most rodent studies [4][8]. TB-500: daily to twice-weekly depending on model. No consensus human protocol exists for either compound.

## Reconstitution of BPC-157 TB-500 Blend

Research protocols describe reconstitution with bacteriostatic water (0.9% benzyl alcohol saline) at 1–2 mg/mL [24]. GHK-Cu solution turns blue-green upon reconstitution — expected copper(II) chelation, not degradation [24]. Storage: −20°C long-term; 2–8°C after reconstitution.

## Timeline: When Do BPC-157 and TB-500 Show Effects in Studies?

BPC-157: measurable tissue changes within 7–14 days [4][8]. Thymosin beta-4 wound studies: reepithelialization changes within 4–7 days [10]. GHK-Cu liposomal: wound closure shortened to 14 days [17]. No validated human timeline exists.

## GHK-Cu Studied Concentrations

Active in fibroblast culture at 10⁻¹² to 10⁻⁹ M (picomolar-to-nanomolar range) [16]. Plasma endogenous levels: ~200 ng/mL at age 20, ~80 ng/mL by age 60 [14]. No injectable synthetic GHK-Cu pharmacokinetic study in published literature; topical formulation strategies are the primary delivery research focus [26].

---

Three growing literatures, one reading room — each study pressed and labeled here, sold by no one and prescribed by no one.